– 1 –
1st Proof • 08/08/2007 • Biosino • 070600649ann(JE)
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION


(Registered in the People’s Republic of China with limited liability)
(Stock Code: 8247)
INTERIM RESULTS ANNOUNCEMENT
FOR THE THREE MONTHS AND SIX MONTHS ENDED 30 JUNE 2007

CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET (THE “GEM”)
OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK
EXCHANGE”)
GEM has been established as a market designed to accommodate companies to which a high
investment risk may be attached. In particular, companies may list on GEM with neither a track
record of profitability nor any obligation to forecast future profitability. Furthermore, there may
be risks arising out of the emerging nature of companies listed on GEM and the business sectors or
countries in which the companies operate. Prospective investors should be aware of the potential
risks of investing in such companies and should make the decision to invest only after due and
careful consideration. The greater risk profile and other characteristics of GEM mean that it is a
market more suited to professional and other sophisticated investors.
Given the emerging nature of companies listed on GEM, there is a risk that securities traded on
GEM may be more susceptible to high market volatility than securities traded on the Main Board
and no assurance is given that there will be a liquid market in the securities traded on GEM.
The principal means of information dissemination on GEM is publication on the internet website
operated by the Stock Exchange. Listed companies are not generally required to issue paid
announcements in gazetted newspapers. Accordingly, prospective investors should note that they
need to have access to the GEM website in order to obtain up-to-date information on GEM-listed
companies.

This announcement, for which the directors (the “Directors”) of Biosino Bio-Technology and Science
Incorporation (the “Company”) collectively and individually accept full responsibilities, includes
particulars given in compliance with the Rules Governing the Listing of Securities on GEM (the “GEM
Listing Rules”) of the Stock Exchange for the purpose of giving information with regard to the Company.
The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and
belief: (1) the information contained in this announcement is accurate and complete in all material
respects and not misleading; (2) there are no other matters the omission of which would make any
statement in this announcement misleading; and (3) all opinions expressed in this announcement have
been arrived at after due and careful consideration and are founded on bases and assumptions that are
fair and reasonable.


– 2 –
1st Proof • 08/08/2007 • Biosino • 070600649ann(JE)
UNAUDITED CONSOLIDATED INTERIM RESULTS

The Board of Directors (the “Board”) of the Company announced the unaudited consolidated results of
the Group for the three months and six months ended 30 June 2007 and the unaudited condensed
consolidated balance sheet of the Group as at 30 June 2007, together with the comparative figures in
2006, as follows:
CONDENSED CONSOLIDATED INCOME STATEMENT

For the three months and six months ended 30 June 2007
Three months ended Six months ended
30 June 30 June
2007 2006 2007 2006

Unaudited Unaudited Unaudited Unaudited
Notes RMB’000 RMB’000 RMB’000 RMB’000
REVENUE 2, 3 47,188 38,171 83,652 68,170

Cost of sales (16,472) (12,664) (29,318) (22,525)
Gross profit 30,716 25,507 54,334 45,645
Other income 2,033 373 3,688 444
Selling and distribution expenses (11,322) (10,703) (18,582) (17,821)
Administrative expenses (11,227) (6,803) (19,776) (12,322)
Research and development costs (2,029) (2,223) (5,018) (4,029)
Other operating expenses (161) – (556) –
PROFIT FROM OPERATING ACTIVITIES 4 8,010 6,151 14,090 11,917

Finance costs 5 (1,390) (496) (2,732) (1,044)
PROFIT BEFORE TAX 6,620 5,655 11,358 10,873

Tax 6 (1,830) (977) (3,294) (1,624)
PROFIT FOR THE PERIOD 4,790 4,678 8,064 9,249

Attributable to:
Shareholders of the Company 4,180 4,364 7,182 8,682
Minority interests 610 314 882 567
4,790 4,678 8,064 9,249
EARNINGS PER SHARE ATTRIBUTABLE TO
SHAREHOLDERS OF THE COMPANY 7

– Basic (RMB) 0.042 0.044 0.072 0.098
– Diluted N/A N/A N/A N/A

– 3 –
1st Proof • 08/08/2007 • Biosino • 070600649ann(JE)
CONDENSED CONSOLIDATED BALANCE SHEET

As at 30 June 2007
30 June 31 December
2007 2006

Unaudited Audited
Notes RMB’000 RMB’000
ASSETS

Non-current assets:
Property, plant and equipment 110,129 111,266
Prepaid land premiums 6,881 6,957
Goodwill 471 309
Know-how 2,219 2,238
Trade and bills receivables 9 1,830 1,530
Total non-current assets 121,530 122,300
Current assets:
Prepaid land premiums 146 146
Inventories 21,492 21,199
Trade and bills receivables 9 37,079 27,963
Prepayments, deposits and other receivables 13,672 10,581
Financial assets at fair value through profit or loss 195 –
Pledged bank balance 3 3
Cash and cash equivalents 149,247 154,580
Total current assets 221,834 214,472
TOTAL ASSETS 343,364 336,772

– 4 –
1st Proof • 08/08/2007 • Biosino • 070600649ann(JE)
30 June 31 December
2007 2006

Unaudited Audited
Notes RMB’000 RMB’000
EQUITY AND LIABILITIES

Equity attributable to shareholders of the Company:
Issued capital 10 100,018 100,018
Reserves 68,014 60,832
Proposed final dividend – 10,002
168,032 170,852

Minority interests 20,328 18,872
TOTAL EQUITY 188,360 189,724

Non-current liabilities:
Government grants 12,820 12,820
Bank borrowings 80,000 80,000
Total non-current liabilities 92,820 92,820
Current liabilities:
Trade and bills payables 11 6,665 2,355
Other payables and accruals 40,125 35,866
Taxes payable 5,394 6,007
Bank borrowings 10,000 10,000
Total current liabilities 62,184 54,228
TOTAL LIABILITIES 155,004 147,048
TOTAL EQUITY AND LIABILITIES 343,364 336,772

– 5 –
1st Proof • 08/08/2007 • Biosino • 070600649ann(JE)
Notes:
1. BASIS OF PREPARATION

The unaudited condensed consolidated accounts for the three months and six months ended 30 June 2007 have been
prepared in accordance with Hong Kong Financial Reporting Standards (“HKFRSs”) (which also include Hong Kong
Accounting Standards (“HKASs”) and Interpretations) issued by the Hong Kong Institute of Certified Public Accountants
(“HKICPA”) and accounting principles generally accepted in Hong Kong. The accounting policies and basis of
preparation used in the preparation of the unaudited condensed consolidated accounts are consistent with those used in
the Company’s audited financial statements for the year ended 31 December 2006.
2. SEGMENT INFORMATION

Segment information is presented by way of two segment formats: (i) on a primary segment reporting basis, by
business segment; and (ii) on a secondary segment reporting basis, by geographical segment.
The Group’s operating businesses are structured and managed separately according to the nature of their operations
and the products they provide. Each of the Group’s business segments represents a strategic business unit that offers
products which are subject to risks and returns that are different from those of the other business segments. Particulars
of the business segments are summarised as follows:
(i) the in-vitro diagnostic reagent products segment manufactures, sells and distributes a variety of mono/double
diagnostic reagent products; and
(ii) the pharmaceutical product segment manufactures, sells and distributes a pharmaceutical product.

– 6 –
1st Proof • 08/08/2007 • Biosino • 070600649ann(JE)
(a) Business segments
The following tables present revenue and results for the Group’s business segments for each of the six months
ended 30 June 2007 and 2006.
Six months ended 30 June 2007
In-virto
diagnostic Pharma-
reagent ceutical
products product Eliminations Total
Unaudited Unaudited Unaudited Unaudited
RMB’000 RMB’000 RMB’000 RMB’000
Segment revenue:
Sales to external customers 54,026 29,626 – 83,652
Other income 2,996 – – 2,996
Total 57,022 29,626 – 86,648
Segment results 9,281 4,117 13,398
Interest income 692
Profit from operating activities 14,090
Finance costs (2,732)
Profit before tax 11,358
Tax (3,294)
Profit for the period 8,064

– 7 –
1st Proof • 08/08/2007 • Biosino • 070600649ann(JE)
Six months ended 30 June 2006
In-virto
diagnostic Pharma-
reagent ceutical
products product Eliminations Total
Unaudited Unaudited Unaudited Unaudited
RMB’000 RMB’000 RMB’000 RMB’000
Segment revenue:
Sales to external customers 43,652 24,518 – 68,170
Other income 24 – – 24
Total 43,676 24,518 – 68,194
Segment results 8,821 2,676 11,497
Interest income 420
Profit from operating activities 11,917
Finance costs (1,044)
Profit before tax 10,873
Tax (1,624)
Profit for the period 9,249
(b) Geographical segments
No geographical segmental analysis is presented as all of the Group’s operations were located in Mainland
China for each of the six months ended 30 June 2007 and 2006.

– 8 –
1st Proof • 08/08/2007 • Biosino • 070600649ann(JE)
3. REVENUE

Revenue, which is also the Group’s turnover, represents the net invoiced value of goods sold, net of value added tax
and government surcharges, and after allowances for the goods returned and trade discounts.
An analysis of the Group’s revenue for the three months and six months ended 30 June 2007 is as follows:
Three months ended Six months ended
30 June 30 June
2007 2006 2007 2006

Unaudited Unaudited Unaudited Unaudited
RMB’000 RMB’000 RMB’000 RMB’000
Sale of in-vitro diagnostic reagent products 30,774 24,622 54,026 43,652
Sale of a pharmaceutical product 16,414 13,549 29,626 24,518
47,188 38,171 83,652 68,170
4. PROFIT FROM OPERATING ACTIVITIES

Profit from operating activities was arrived at after charging:
Three months ended Six months ended
30 June 30 June
2007 2006 2007 2006

Unaudited Unaudited Unaudited Unaudited
RMB’000 RMB’000 RMB’000 RMB’000
Depreciation 2,551 1,888 4,973 3,319
Amortisation of know-how 108 107 214 185
Amortisation of prepaid land premiums 39 37 77 73
5. FINANCE COSTS

Three months ended Six months ended
30 June 30 June
2007 2006 2007 2006

Unaudited Unaudited Unaudited Unaudited
RMB’000 RMB’000 RMB’000 RMB’000
Interest on bank loans 1,390 496 2,732 1,044

– 9 –
1st Proof • 08/08/2007 • Biosino • 070600649ann(JE)
6. TAX

No provision for Hong Kong profits tax has been made as the Group did not generate any assessable profits arising in
Hong Kong during the six months ended 30 June 2007 (2006: Nil). Taxes on profits assessable elsewhere have been
calculated at the rates of tax prevailing in the countries in which the Group operates, based on existing legislation,
interpretations and practices in respect thereof. According to the relevant PRC income tax law, the Company and its
subsidiaries, being registered as new and high technology enterprises in Beijing, are entitled to concessionary income
tax rates of 15% and 7.5% in their respective subsidiaries, which have been applied for both periods.
Three months ended Six months ended
30 June 30 June
2007 2006 2007 2006

Unaudited Unaudited Unaudited Unaudited
RMB’000 RMB’000 RMB’000 RMB’000
Group:
Current – Mainland China 1,830 977 3,294 1,624
7. EARNINGS PER SHARE

The calculation of basic earnings per share for the three months ended 30 June 2007 is based on the unaudited profit
attributable to shareholders of the Company for the period and the weighted average of 100,017,528 (2006: 100,017,528)
registered shares in issue during the period.
The calculation of basic earnings per share for the six months ended 30 June 2007 is based on the unaudited profit
attributable to shareholders of the Company for the period and the weighted average of 100,017,528 (2006: 88,693,025)
registered shares in issue during the period.
No diluted earnings per share have been presented as no diluting event existed during the three months and six months
ended 30 June 2007 (2006: Nil).
8. INTERIM DIVIDEND

The Board does not recommend the payment of an interim dividend for the six months ended 30 June 2007 (2006:
Nil).
9. TRADE AND BILLS RECEIVABLES

The credit period of the Group to its customers is generally for a period ranging from 60 days to 90 days. The Group
closely monitors overdue balances, and impairment is made when it is considered that amounts due may not be
recovered. In view of the aforementioned and the fact that the Group’s trade receivables relate to a large number of
diversified customers, there is no significant concentration of credit risk. Trade receivables are non-interest-bearing.

– 10 –
1st Proof • 08/08/2007 • Biosino • 070600649ann(JE)
An aged analysis of the trade and bills receivables of the Group as at the balance sheet date based on invoice date, are
as follows:
30 June 31 December
2007 2006

Unaudited Audited
RMB’000 RMB’000
Within 3 months 30,883 22,778
4 to 6 months 4,062 2,361
7 to 12 months 2,296 1,749
1 to 2 years 2,378 3,084
Over 2 years 2,023 1,674
41,642 31,646

Less: Provision for doubtful receivables (2,733) (2,153)
38,909 29,493

Less: Portion classified as current assets (37,079) (27,963)
Non-current portion 1,830 1,530
Included in the trade and bills receivables of the Group as at 30 June 2007 was an aggregate amount of RMB1,830,000
(as at 31 December 2006: RMB1,530,000) due from certain established customers of the Group for several instalment
sales contracts entered into with payment terms ranging from two to four years. The balances are unsecured and
interest-free.
The carrying amounts of the trade and bills receivables approximate to their fair values.
10. SHARE CAPITAL

30 June 31 December
2007 2006

Unaudited Audited
RMB’000 RMB’000
Registered, issued and fully paid:
67,017,528 Domestic shares of RMB1.00 each 67,018 67,018
33,000,000 H shares of RMB1.00 each 33,000 33,000
100,018 100,018

– 11 –
1st Proof • 08/08/2007 • Biosino • 070600649ann(JE)
11. TRADE AND BILLS PAYABLES

An aged analysis of trade and bills payables of the Group as at the balance sheet date, based on the invoice date, is as
follows:
30 June 31 December
2007 2006

Unaudited Audited
RMB’000 RMB’000
Outstanding balances aged:
Within 3 months 6,098 1,744
4 to 6 months 118 322
7 to 12 months 324 73
1 to 2 years 54 114
Over 2 years 71 102
6,665 2,355

The trade payables are non-interest-bearing and are normally settled on credit terms ranging from 30 days to 90 days.
MANAGEMENT DISCUSSION AND ANALYSIS

Business Review for the First Half of 2007
For the first half of the year, an important project of “Bio-medical Key Reagent”[J<
, the first project supporting the development of in-vitro diagnostic reagent of the 863 Program
under the Eleventh Five-Year Plan of the State, has come into its full implementation. The Group, as the
leader of in-vitro diagnostic reagent production in China, undertakes and leads the implementation of
such project. Moreover, the State Food and Drug Administration of the PRC (“SFDA”) officially issued
and implemented the “Management Method of In Vitro Diagnostic Reagents Registration (Interim)”
.bWM#l,during the first half of the year, and some relevant ancillary
regulations including “Detailed Rules for the Implementation of the Production of In Vitro Diagnostic
Reagents (Interim)”.b[DZ, “Guiding Principles for the Preparation
of Manuals for In Vitro Diagnostic Reagents”.b38awere issued
afterward. Such regulation is the State’s first regulation specific to in-vitro diagnostic reagents, the
issuance and implementation of which not only provides the Company with new concepts, new policies
and new demands, but also presents new opportunities and targets for the Company. As a leading enterprise
in the in-vitro diagnostic reagent industry, the Group has already prepared itself to meet the new standards.
The implementation of these new regulations will enhance the industry’s orderly development to reach
high standards and requirements, and will also facilitate the growth of the Group. Since this year, the
State has put additional resources in public hospital services and insurance for the low-income group.
This has already driven the market growth of the in-vitro diagnostic industry and created higher demands
for the Group’s products.

– 12 –
1st Proof • 08/08/2007 • Biosino • 070600649ann(JE)
For the first half of the year, the Group took full advantage of the opportunities brought by the development
of China and devoted more resources to product research and development as well as infrastructure
construction. We also adopted an active approach in expanding the product mix and target market,
thereby facilitating the trend of healthy and rapid growth of our businesses.
Financial Review for the First Half of 2007
The revenue for the six months ended 30 June 2007 was approximately RMB83.65 million, representing
a remarkable increase of 22.7% as compared with approximately RMB68.17 million for the corresponding
period last year. The revenue of approximately RMB54.03 million of in-vitro diagnostic reagent products
accounted for 64.6% of the Group’s total revenues, representing a 23.8% increase as compared with
RMB43.65 million over the corresponding period last year. For pharmaceutical products, the revenue of
RMB29.62 million of Lumbrokinase capsules accounted for 35.4% of the Group’s total revenue,
representing an increase of 20.8% as compared with RMB24.52 million over the corresponding period
last year.
For the six months ended 30 June 2007, profit from operating activities amounted to RMB14.09 million,
representing an increase of 18.3% as compared with the corresponding period last year. With an aim to
promote business expansion and further consolidate its leading position in the market, the Group continued
its effort in the research and development of new diagnostic reagent products and pharmaceutical products,
and thereby recorded higher research and development expenses. On the other hand, the surge in operating
expenses as compared with the corresponding period last year was mainly attributable to the consolidation
of operational expenses of four subsidiaries which were established or acquired by the Group since the
end of the first quarter last year, offsetting part of the increase in profit generated from the out-performed
growth in sales.
Profit attributable to shareholders for the six months ended 30 June 2007 was RMB7.18 million,
representing a decrease of approximately 17.3% as compared with the corresponding period last year.
Such decrease was mainly attributable to the increase in interest expenses as a result of the increase in
the Group’s bank borrowings for research and development and business expansion, together with the
higher income tax expense due to the adjustment in the fixed deductible amount on salary expenses by
State Administration of Taxation.

– 13 –
1st Proof • 08/08/2007 • Biosino • 070600649ann(JE)
Prospect and Outlook
Looking forward, the Group is confident about the prospect of development of the in-vitro diagnostic
reagent industry and of the Group. By actively carrying out the State’s 863 Program and establishing a
technological innovation system for China’s medical test and in-vitro diagnostic reagent industry, we will
give full support to the State’s policy of “establishing a technological innovation system with enterprises
as the subject, market trend as the guide and the construction of a system embracing manufactures,
studies and researches”. On the other hand, we will also make greater efforts in the research and
development of new products, as well as enhance our self-innovation capability by setting up a reference
system and an industry standard system, with an aim to increase our share in the China market and export
our products.
Besides, in view of the long-term growth, the Group will step up its efforts in expanding product mix and
enhancing market network. By maintaining a team with talented staff and establishing an industrial
system with high productivity and competitiveness, the Group can sustain its development and become a
pioneer in China’s protein industry with international influence, which in turn maximizing our shareholders’
interest.
Purchase, Sale or Redemption of the Company’s Listed Securities
Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company’s listed
securities during the period.
Compliance Adviser’s Interest
As updated and notified by the Company’s compliance adviser, Partners Capital International Limited
(the “Compliance Adviser”), none of the Compliance Adviser, or its directors, employees or associates
(as defined under the GEM Listing Rules) had any interest in the share capital of the Company as at 30
June 2007 pursuant to Rule 6.36 of the GEM Listing Rules.
Pursuant to an agreement dated 27 February 2006 entered into between the Company and the Compliance
Adviser, the Compliance Adviser will receive a fee for acting as the Company’s compliance adviser for
the period from 27 February 2006 and end on the date on which the Company complies with Rule 18.03
of the GEM Listing Rules in respect of its financial results for the second full financial year ending 31
December 2008 or until the agreement is terminated in accordance with the terms and conditions set out
therein.

– 14 –
1st Proof • 08/08/2007 • Biosino • 070600649ann(JE)
Corporate Governance and Compliance with the Code on Corporate Governance Practices
The Company always puts strong emphasis on the superiority, steadiness and rationality of corporate
governance. The Company has complied with all the code provisions in the Code on Corporate Governance
Practice (the “Code”) by establishing a formal and transparent procedures to protect and maximise the
interests of shareholders during the period under review, except for the deviation that Mr. Wu Lebin
assumes the role of both the chairman of the Board and the president of the Company. The Board is of
the view that it is in the best interests of the Group to have Mr. Wu, who have vast and solid experience
in the medical industry to perform the dual role so that the Board can have the benefits of a chairman
who is knowledgeable about the business of the Group and is most capable to guide and brief the Board
in a timely manner on pertinent issues.
Audit Committee
The Company has established an audit committee on 10 February 2006 with written terms of reference in
compliance with the requirements as set out in Rules 5.28 and 5.29 of the GEM Listing Rules. The audit
committee’s primary duties are the review and supervision of the Company’s financial reporting procedures
and internal control system. The Group’s unaudited condensed consolidated accounts for the six months
ended 30 June 2007 have been reviewed by the audit committee with the three independent non-executive
directors of the Company, namely Dr. Cheng Jing (appointed on 9 January 2007), Dr. Hua Sheng and Mr.
Chan Yiu Kwong.
By order of the Board
Biosino Bio-Technology and Science Incorporation
Mr. Wu Lebin
Chairman
Beijing, the PRC, 8 August 2007

– 15 –
1st Proof • 08/08/2007 • Biosino • 070600649ann(JE)
As at the date of this announcement, the Board comprises:
Chairman and Executive Director
Mr. Wu LebinN!s[
Vice Chairman and Non-executive Directors
Mr. Zhang Yongu[and Dr. Gao Guang Xia{
Executive Directors
Dr. Wang Lin{and Mr. Hou QuanminO[
Non-executive Directors
Ms. Li Chang~{, Mr. Rong Yangq[, Mr. Wang Fu GenE[and Ms. Yu
XiaominO~{
Independent non-executive Directors
Dr. Cheng Jing/{, Dr. Hua Sheng6[{and Mr. Chan Yiu Kwong4[
This announcement, for which the Directors collectively and individually accept full responsibility, includes
particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise
Market of The Directors, having made all reasonable enquiries, confirm that, to the best of their
knowledge and belief, (1) the information contained in this announcement is accurate and complete in all
material respects and not misleading; (2) there are no other matters the omission of which would make
any statement in this announcement misleading; and (3) all opinions expressed in this announcement
have been arrived at after due and careful consideration and are founded on bases and assumptions that
are fair and reasonable.
This announcement will remain on the “Latest Company Announcements” page of the GEM website for
at least seven days from the day of its posting.